Gain Therapeutics Shares Are Trading Lower. The Company Announced Positive From the Phase 1 Study Conducted to Evaluate the Safety, Tolerability and Pharmacokinetics of GT-02287.
Gain Therapeutics Shares Are Trading Lower. The Company Announced Positive From the Phase 1 Study Conducted to Evaluate the Safety, Tolerability and Pharmacokinetics of GT-02287.
蓋恩療法（Gain Therapeutics）股票價格下跌。該公司宣佈了對Gt-02287進行的一期研究結果，該研究旨在評估Gt-02287的安全性、耐受性和藥代動力學。
Gain Therapeutics Shares Are Trading Lower. The Company Announced Positive From the Phase 1 Study Conducted to Evaluate the Safety, Tolerability and Pharmacokinetics of GT-02287.
蓋恩療法（Gain Therapeutics）股票價格下跌。該公司宣佈了對Gt-02287進行的一期研究結果，該研究旨在評估Gt-02287的安全性、耐受性和藥代動力學。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。